INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Flood, Amar Hugh
Dobscha, James Robert
Abstract
The present disclosure concerns scalable single-pot synthesis, anion binding features, liquid-liquid extraction of salts of the triazolophane macrocycle of Formula (I):
The present disclosure concerns scalable single-pot synthesis, anion binding features, liquid-liquid extraction of salts of the triazolophane macrocycle of Formula (I):
The present disclosure concerns scalable single-pot synthesis, anion binding features, liquid-liquid extraction of salts of the triazolophane macrocycle of Formula (I):
wherein the substituents R are independently selected from the group consisting of a linear and branched alkyl, a linear and branched alkyl substituted with an ionizable functional group such as an amine or carboxylic acid, a linear and branched alkoxy (R=—OR), an alkyl comprising —O(CH2CH2O)nCH3, where n is 1-20, an amide —CO—NR1R2, where R1 is any alkyl, organic substituent, R2 is any alkyl, organic substituent, wherein R1 and R2 may be identical or different, —OCO—R, wherein R is any alkyl, organic substituent, an aromatic ring and their substituted analogues, any length and sequence of natural and unnatural amino acids that make up a peptide chain, and —C≡C—R where R is any alkyl, organic substituent.
C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
C02F 1/68 - Treatment of water, waste water, or sewage by addition of specified substances, e.g. trace elements, for ameliorating potable water
C02F 101/12 - Halogens or halogen-containing compounds
2.
Hydrodynamic Methods for Delivering Fluids to Kidney Tissues and Related Materials and Methods
Indiana University Research & Technology Corporation (USA)
United States Government as Represented by the Department of Veterans Affairs (USA)
Inventor
Bacallao, Robert
Atkinson, Simon
Rhodes, George
Corridon, Peter
Abstract
The present invention provides methods and materials useful delivering liquids, including liquids comprising nucleic acid molecules into cells. In particular, the present invention provides methods for delivering saline solution, exogenous compositions, and isolated vectors to kidney cells, using the renal vein as a guide and under hydrodynamic pressure. The delivery methods and materials herein are useful to research, prognose, ameliorate symptoms of kidney injury, and treat kidney pathologies.
Indiana University Research & Technology Corporation (USA)
Inventor
Pelus, Louis M.
Hoggatt, Jonathan
Singh, Pratibha
Abstract
This disclosure is directed to the methods of enhancing hematopoietic stem cells (HSPC) and progenitor cell (HSPC) engraftment procedure. Treatment in vivo of a HSPC donor with compounds that reduce PGE2 biosynthesis or PGE2 receptor antagonists alone, or in combination with other hematopoietic mobilization agents such as AMD3100 and G-CSF, increases the circulation of available HSPCs. Compounds that reduce the cellular synthesis of PGE2 include non−steroidal anti-inflammatory compounds such as indomethacin. Treatment ex vivo of HSPC with an effective amount of PGE2 or at least one of its derivatives such as 16,16-dimethyl prostaglandin E2 (dmPGE2), promotes HSPC engraftment. Similar methods may also be used to increase viral-mediated gene transduction efficacy into HSPC.
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Flood, Amar, Hugh
Dobscha, James, Robert
Abstract
22n33, where n is 1-20, an amide -CO-NR1R2, where R1is any alkyl, organic substituent, R2is any alkyl, organic substituent, wherein R1and R2 may be identical or different, -OCO-R, wherein R is any alkyl, organic substituent, an aromatic ring and their substituted analogues, any length and sequence of natural and unnatural amino acids that make up a peptide chain, and -C≡C-R where R is any alkyl, organic substituent.
C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
B01J 20/22 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising organic material
Indiana University Research & Technology Corporation (USA)
Inventor
Rodefeld, Mark D.
Abstract
Methods and devices for a self-contained device including a hydraulic motor and a hydraulic pump. Preferably, the motor is incorporated either within the interior of the pump, on the exterior of the pump, or a combination of the two. The pump increases the kinetic energy of the fluid by centrifugal means, and in some embodiments is a viscous impeller pump. Applications include building flow systems, industrial processes, and biological circulatory systems.
A61M 60/405 - Details relating to driving for non-positive displacement blood pumps the force acting on the blood contacting member being hydraulic or pneumatic
A61M 60/148 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable via, into, inside, in line, branching on, or around a blood vessel in line with a blood vessel using resection or like techniques, e.g. permanent endovascular heart assist devices
Indiana University Research & Technology Corporation (USA)
Georgia Tech Research Corporation (USA)
Inventor
Wang, Xiaofeng
Yuan, Kan
Liao, Xiaojing
Beyah, Raheem A.
Abstract
System and method for detecting an infected website are disclosed. A semantic finder receives top-level domains and identifies keywords of the top-level domains representing a predetermined semantics. The keywords are compared with irrelevant bad terms to find at least one irrelevant term. An inconsistency searcher searches the top-level domains and detects at least one fully-qualified domain name carrying the at least one irrelevant term. A context analyzer evaluates context information associated with the irrelevant term, identifies at least one frequently-used term identified in the context information, and determines whether the at least one frequently-used term is unrelated to a generic content of the at least one fully-qualified domain name An irrelevant bad term collector extracts the at least one frequently-used term unrelated to the generic content and adds the extracted frequently-used term to an irrelevant bad term list for detecting the infected website.
Indiana University Research & Technology Corporation (USA)
Inventor
Agarwal, Mangilal
Varahramyan, Khodadad
Shrestha, Sudhir
Daneshkhah, Ali
Abstract
A biomedical sensor and sensor system for analysis of breath are disclosed. The biomedical sensor can include two layers arranged to swell or contract in a plane perpendicular to an axial direction while being restricted from swelling in the axial direction. The biomedical sensor includes resistance connections to allow measurement of the resistance of each layer and a combined resistance of both layers. The sensor system can include one, two, or three or more sensors, each having a pair of electrodes separated by a gap and one or more layers of composite material located within the gap. the sensor system includes resistance circuits configured to measure changes in resistance between the electrodes. A polypyrrole/polymethyl methacrylate/polyethylene glycol composite material and method of making the same are disclosed.
G01N 33/497 - Physical analysis of biological material of gaseous biological material, e.g. breath
G01N 33/98 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving alcohol, e.g. ethanol in breath
G01N 33/64 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving ketones
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
C08L 79/04 - Polycondensates having nitrogen-containing heterocyclic rings in the main chainPolyhydrazidesPolyamide acids or similar polyimide precursors
C08L 33/12 - Homopolymers or copolymers of methyl methacrylate
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Mirmira, Raghavendra G.
Abstract
Disclosed herein are methods for determining inflammation in subjects. Also disclosed are methods for determining whether a subject has sepsis. The methods include determining methylation of preproinsulin DNA.
A61P 5/00 - Drugs for disorders of the endocrine system
C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
C40B 40/10 - Libraries containing peptides or polypeptides, or derivatives thereof
C40B 50/02 - In silico or mathematical conception of libraries
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Blazer-Yost, Bonnie Lucille
Abstract
Methods for inhibiting transepithelial ion transport, inhibiting hydrocephalic development, and for treating hydrocephalus are disclosed herein. The methods include administering a potassium channel inhibitor to the individual. In one particular embodiment, the individual is administered the calcium-activated potassium channel inhibitor, fluoxetine.
C07C 217/48 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61P 25/00 - Drugs for disorders of the nervous system
10.
MONOHYDROXYLATED 17ALPHA-HYDROXYPROGESTERONE CAPROATE FOR REDUCING CONTRACTILITY
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Patil, Avinash Shivaputrappa
Abstract
A monohydroxylated 17α-hydroxyprogesterone caproate (HPC-OH), 17α-hydroxyprogesteryl 6-hydroxycaproate, is disclosed herein for reducing uterine contractions, reducing inflammation related to contractility, and preventing preterm birth. Additionally, the use of HPC-OH as a diagnostic is also disclosed.
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
11.
QUANTITATIVE PROFILING OF PROGESTERONE METABOLITES FOR THE PREDICTION OF SPONTANEOUS PRETERM DELIVERY
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Patil, Dr. Avinash Shivaputrappa
Abstract
Disclosed are methods for identifying a pregnant female who is susceptible to spontaneous preterm delivery. In particular, disclosed are methods for identifying a pregnant female who is susceptible to spontaneous preterm delivery based on ratios of steroids in samples obtained from the pregnant female.
C07J 1/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, not substituted in position 17 beta by a carbon atom, e.g. oestrane, androstane
C07J 5/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, and substituted in position 21 by only one singly bound oxygen atom
C07J 51/00 - Normal steroids with unmodified cyclopenta[a]hydrophenanthrene skeleton not provided for in groups
G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Patil, Avinash Shivaputrappa
Abstract
Disclosed are methods for identifying a pregnant female who is susceptible to spontaneous preterm delivery. In particular, disclosed are methods for identifying a pregnant female who is susceptible to spontaneous preterm delivery based on ratios of steroids in samples obtained from the pregnant female.
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Sardar, Rajesh
Korc, Murray
Joshi, Gayatri K.
Abstract
Biosensors and methods for localized surface plasmon resonance biosensing are disclosed. The biosensor can include a substrate having a substrate surface to which a plurality of localized surface plasmon resonance (LSPR) antennae are affixed. The LSPR antennae can be affixed via an affixation surface of the LSPR antenna. The LSPR antennae can have a functional surface opposite the affixation surface. Each functional surface can be functionalized by a plurality of single-stranded DNA.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
SCRIPPS RESEARCH INSTITUTE (USA)
THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS OFFICE OF GENERAL COUNSEL (USA)
Inventor
Niculescu, Dr. Alexander B.
Petrascheck, Dr. Michael
Abstract
The present disclosure relates generally to genes and biological pathways involved in the active regulation by mood and stress of life expectancy, in all subjects, and separately by gender. Some of these represent a life switch between suicide and longevity. Disclosed are methods for identifying compounds involved in the modulation of active longevity by mood and stress, in particular compounds that modulate the life switch, and thus, modulate active longevity. Also disclosed are methods for increasing active longevity in a subject in general, and modulating the life switch in a subject with psychiatric disorders in particular. Also disclosed are methods for determining biological age score in a subject in general, and predicting lifespan/time to death from all causes in subjects.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Clauss, Matthais, A.
Maier, Bernhard, F.
Abstract
Provided herein are methods of treating HIV infection, including retention of HIV+ T cells in viral reservoirs such as lymph nodes. More particularly, provided herein are methods in which an effective amount of a HIV Nef pathway inhibitor (e.g., anti-Nef agent) is administered to a subject in need thereof, whereby administration of the inhibitor treats HIV infection in the subject, decreases retention of HIV+ T cells in lymph nodes, and increases migration of HIV+ T cells from lymph nodes.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Bogatcheva, Natalia, V.
Clauss, Matthias, A.
March, Keith L.
Abstract
EMAPII is a monocyte- and endothelial cell-activating protein with prominent pro- apoptotic activity on endothelial and epithelial cells. Provided herein are compositions and methods for treating or preventing endothelial and epithelial apoptosis induced by EMAPII. More particularly, provided herein are compositions and methods for treating or preventing Influenza A virus (IAV)-induced weight loss, impairment of blood oxygenation, lung edema, and endothelial/epithelial apoptosis associated with IAV infections. In addition, anti-EMAPII therapy provides a novel complementary treatment strategy to existing anti-viral and anti-inflammatory approaches
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (USA)
Inventor
Androphy, Elliot J.
Hodgetts, Kevin
Calder, Alyssa Nicole
Abstract
Disclosed herein are compositions and methods for treatment of spinal muscular atrophy (SMA). In certain embodiments, compounds are provided that increase full-length survival of motor neuron (SMN) protein production by an SMN2 gene.
A61K 31/4353 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
A61K 31/429 - Thiazoles condensed with heterocyclic ring systems
19.
Methods for generating the inner ear and other cranial placode-derived tissues using pluripotent stem cells
Indiana University Research & Technology Corporation (USA)
Inventor
Hashino, Eri
Oxford, Gerry
Koehler, Karl R.
Abstract
Disclosed herein are methods and compositions for generating cultures and isolated cell populations containing preplacodal ectoderms cells, otic placode cells, and inner ear sensory hair cells derived from pluripotent cells by modulating TGFβ, BMP, and FGF signaling pathways under defined culture conditions. Also described are methods for obtaining non-otic placodal tissues from pluripotent stem cells. Methods for identifying agents that induce or enhance differentiation and generation of hair cells are also disclosed. Methods for identifying cytoprotective agents for hair cells are also described.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Yan, Cong
Du, Hong
Abstract
Methods of cancer treatment are disclosed. Particularly, disclosed herein are methods of administering LAL and PPARγ ligands for treating various cancer patients to promote anti-cancer immunity immunity (suppress MDSCs), use for inhibiting tumor progression, and use for inhibiting tumor metastasis.
INDIANA UNIVERSTTY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Chen, Peng-Sheng
Abstract
System and methods for monitoring and/or controlling nerve activity in a subject are provided. In one embodiment, a system includes electrodes configured to be placed proximate to a subject's skin, and a signal detector configured to detect electrical signals using the electrodes. The system also includes a signal processor configured to receive the electrical signals from the signal detector, and apply a filter to the received electrical signals to generate filtered signals, the filter configured to attenuate at least signals having frequencies corresponding to heart muscle activity during a heartbeat. The signal processor is also configured to identify a skin nerve activity using the filtered signals, estimate a sympathetic nerve activity using the identified skin nerve activity, and further to generate a report indicative of the estimated sympathetic nerve activity. In some aspects, the system further includes a signal generator to deliver the electrical stimulation to the subject's skin.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Pili, Roberto
Abstract
Compositions including combinations of class I histone deacetylase (HDAC) inhibitors and programmed cell death protein 1 (PD-1) inhibitors for enhancing antitumor activity are disclosed. Further disclosed are methods of administering these compositions as immunotherapies for suppressing regulatory T cells in renal cell carcinoma.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Petrache, Irina
Queini, Houssam
March, Keith
Broxmeyer, Hal
Abstract
Disclosed are methods for treating chronic obstructive pulmonary disease (COPD), and more particularly emphysema. The present disclosure relates to methods for repairing lung tissue damage caused by COPD by administering AMD3100.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Corson, Timothy William
Sulaiman, Rania
Abstract
Compositions including the combination of cremastranone analogs and anti-angiogenic agents and the use of the compositions for targeting ocular angiogenesis such as seen in neovascular eye diseases are disclosed.
A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
25.
METHODS AND COMPOSITIONS FOR TREATING LUNG DISEASE OF PREMATURITY
INDIANA UNIVERSITY RESEARCH &TECHNOLOGY CORPORATION (USA)
Inventor
Schwarz, Margaret, Arlene
Lee, Dong Il
Abstract
The disclosure relates to methods of treating an infant having or at risk of developing bronchopulmonary dysplasia, including premature infants, by administering an antagonist of endothelial monocyte-activating polypeptide II (EMAP II) to the infant.
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
26.
ANTIBIOTIC GEL FORMULATION AND METHODS OF PREPARING THE ANTIBIOTIC GEL FORMULATION
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Yassen, Ghaeth H, Dr.
Platt, Jeffrey A, Dr.
Gregory, Richard L, Dr.
Abstract
Antibiotic gel formulations for use in dental applications are disclosed. More particularly, the present disclosure is directed to antibiotic gel formulations including low concentrations of antibiotics that are capable of killing root canal pathogens without harming the stem cells inside the root canal. Additionally, the present disclosure is directed to delivery systems and methods for applying the antibiotic gel formulations into a subject's intracanal region.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Yassen, Dr. Ghaeth H.
Platt, Dr. Jeffrey A.
Gregory, Dr. Richard L.
Abstract
Antibiotic gel formulations for use in dental applications are disclosed. More particularly, the present disclosure is directed to antibiotic gel formulations including low concentrations of antibiotics that are capable of killing root canal pathogens without harming the stem cells inside the root canal. Additionally, the present disclosure is directed to delivery systems and methods for applying the antibiotic gel formulations into a subject's intracanal region.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
UNIVERSITÉ LIBRE DE BRUXELLES (Belgium)
Inventor
Mirmira, Raghavendra G.
Tersey, Sarah A.
Eizirik, Decio Laks
Fuks, Francois
Abstract
Disclosed herein are compositions and methods for determining new-onset type 1 diabetes, methylation-specific polymerase chain reaction assays for determining new-onset type 1 diabetes, methods for distinguishing between type 1 diabetes and type 2 diabetes, methods for dysglycemia in obese adolescent subjects including obese adolescent subjects having type 2 diabetes and methylation-specific polymerase chain reaction assays for determining dysglycemia in obese adolescent subjects including obese adolescent subjects having type 2 diabetes.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Tector Iii, A., Joseph
Abstract
The application provides methods of improving a rejection related symptom, reducing premature separation and methods of producing a compound of interest with an altered epitope profile are provided. Transgenic pigs with a disrupted gene or genes, and porcine organs, tissues, and cells therefrom are provided.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Niculescu, Alexander
Abstract
Biomarkers and methods for screening expression levels of the biomarkers for predicting suicidality (referred herein to suicidal ideation and actions, future hospitalizations and suicide completion) are disclosed. Also disclosed are quantitative questionnaires and mobile applications for assessing affective state and for assessing socio-demographic and psychological suicide risk factors, and their use to compute scores that can predict suicidality. Finally, an algorithm that combines biomarkers and computer apps for identifying subjects who are at risk for committing suicide is disclosed, as well as methods to mitigate and prevent suicidality based on the biomarkers and computer apps.
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
G01N 33/96 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood or serum control standard
31.
PREDICTING SUICIDALITY USING A COMBINED GENOMIC AND CLINICAL RISK ASSESSMENT
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Niculescu, Dr. Alexander
Abstract
Biomarkers and methods for screening expression levels of the biomarkers for predicting suicidality (referred herein to suicidal ideation and actions, future hospitalizations and suicide completion) are disclosed. Also disclosed are quantitative questionnaires and mobile applications for assessing affective state and for assessing socio-demographic and psychological suicide risk factors, and their use to compute scores that can predict suicidality. Finally, an algorithm that combines biomarkers and computer apps for identifying subjects who are at risk for committing suicide is disclosed, as well as methods to mitigate and prevent suicidality based on the biomarkers and computer apps.
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
G01N 33/96 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood or serum control standard
G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
G06F 19/18 - for functional genomics or proteomics, e.g. genotype-phenotype associations, linkage disequilibrium, population genetics, binding site identification, mutagenesis, genotyping or genome annotation, protein-protein interactions or protein-nucleic acid interactions
32.
PROTEIN TYROSINE PHOSPHATASES OR SHP2 INHIBITORS AND USES THEREOF
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Zhang, Zhong-Yin
He, Rongjun
Abstract
Small molecule compounds derived from α-sulfophenylacetic amide (SPAA) are provided as novel sulfonic acid based pTyr mimetics. These compounds effectively inhibit a variety of protein tyrosine phosphatases (PTPs), such as mPTPA, mPTPB, LMWPTP, and Laforin. Use of these compounds as pharmaceutical agents for treating diseases associated with abnormal protein tyrosine phosphatase activity is also provided.
C07C 317/02 - SulfonesSulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
C07C 317/08 - SulfonesSulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
C07C 317/18 - SulfonesSulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
33.
SMALL MOLECULE INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES AND USES THEREOF
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Zhang, Zhong-Yin
He, Rongjun
Abstract
Small molecule compounds derived from α-sulfophenylacetic amide (SPAA) are provided as novel sulfonic acid based pTyr mimetics. These compounds effectively inhibit a variety of protein tyrosine phosphatases (PTPs), such as mPTPA, mPTPB, LMWPTP, and Laforin. Use of these compounds as pharmaceutical agents for treating diseases associated with abnormal protein tyrosine phosphatase activity is also provided.
Indiana University Research & Technology Corporation (USA)
Inventor
Flood, Amar
Hirsch, Brandon E.
Lee, Semin
Tait, Steven L.
Dobscha, James
Abstract
Disclosed herein are compositions of tricarbazole triazolophane (tricarb) of Formulas (I), (II) and (III):
18), alkyl-substituted phenyl derivatives, and substituted glycol derivatives, or a combination thereof. The disclosure presents examples of thin films composed of the same as well as methods of binding anions from the same.
C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
C02F 1/68 - Treatment of water, waste water, or sewage by addition of specified substances, e.g. trace elements, for ameliorating potable water
B01J 47/12 - Ion-exchange processes in generalApparatus therefor characterised by the use of ion-exchange material in the form of ribbons, filaments, fibres or sheets, e.g. membranes
B01J 45/00 - Ion-exchange in which a complex or a chelate is formedUse of material as complex or chelate forming ion-exchangersTreatment of material for improving the complex or chelate forming ion-exchange properties
B01J 20/22 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising organic material
B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Harris, Alon
Guidoboni, Giovanna
Abstract
This disclosure provides systems and methods for patient-specific identification and assessment of ocular disease risk factors and efficacy of various treatments. The systems and methods can include mathematically modeling an expected normal patient-specific value of one or more clinically observable properties using a patient-specific mathematical model that can be calibrated with patient-specific data. The expected normal patient-specific value can be compared with a measured patient-specific value. A greater difference between the expected and measured patient-specific values can correlate to greater ocular vasculature abnormalities.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Kelley, Mark R.
Fishel, Melissa
Abstract
Methods for targeting apurinic/apyrimidinic endonuclease1/redox effector factor 1 (APEl/Ref-1) are disclosed. More particularly, methods for inhibiting APEl/Ref-1 and hypoxia-mediated signaling for decreasing survival and invasion of tumor cells exposed to hypoxic conditions are disclosed.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Kelley, Mark R.
Fishel, Melissa
Abstract
Methods for targeting apurinic/apyrimidinic endonuclease1/redox effector factor 1 (APEl/Ref-1) are disclosed. More particularly, methods for inhibiting APEl/Ref-1 and hypoxia-mediated signaling for decreasing survival and invasion of tumor cells exposed to hypoxic conditions are disclosed.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Zhang, Jian-Ting
Liu, Jing-Yuan
Abstract
Methods for treating various cancers by administering one or more compounds that target the dimeric protein survivin are disclosed. Pharmaceutical compositions containing such compounds are also disclosed, along with general methods of identifying anti-cancer compounds that target oncogenic dimeric proteins. Exemplary compounds that can be used in the disclosed methods of treatment and pharmaceutical compositions have the chemical structure.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Paczesny, Sophie
Abstract
Cell culture systems for producing IL-33 induced T9 cells and methods of using the IL-33 induced T9 cells (T9IL-33 cells) in a cell therapy for increasing anti-tumoral activity following allogeneic hematopoietic cell transplantation (HCT) and/or treating graft-versus-host disease (GVHD) are disclosed herein. Further, methods of using the T9IL-33 cells, alone or in combination with allogeneic hematopoietic cell transplantation, are described herein for cancer treatment.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Akingba, A., George
Abstract
A system and a method for disrupting an occlusion within a blood vessel is provided The system includes an elongated catheter body having a proximal portion, a distal portion, and a first lumen. The system further includes an ultrasound transmitter extending longitudinally through the first lumen of the catheter body and having a proximal end and a distal end. The system further includes a positioning mechanism located at a distal end of the catheter body. The positioning mechanism has a first retracted position and a second deployed position, and the positioning mechanism is radially expandable from the first retracted position to the second deployed position to position the catheter in the blood vessel.
A61B 8/12 - Diagnosis using ultrasonic, sonic or infrasonic waves in body cavities or body tracts, e.g. by using catheters
A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for
A61M 25/01 - Introducing, guiding, advancing, emplacing or holding catheters
41.
A TH17-PRONE CD146+CCR5+ T-CELL POPULATION AS AN EARLY MARKER OF INTESTINAL GRAFT-VERSUS-HOST DISEASE
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Paczesny, Sophie
Abstract
Th17-prone CD146+CCR5+ T-cell population as an early biomarker of intestinal graft-versus-host disease and its use for determining prognosis of intestinal GVHD before the clinical signs are apparent are disclosed.
G01N 33/567 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent utilising isolate of tissue or organ as binding agent
42.
CULTURE CONDITIONS THAT ALLOW ZYMOMONAS MOBILIS TO ASSIMILATE N2 GAS AS A NITROGEN SOURCE DURING BIO-ETHANOL PRODUCTION
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Mckinlay, James
Posto, Amanda
Lasarre, Breah
Kremer, Timothy
Abstract
Chemically defined culture medium and culture conditions that allow bacteria to assimilate dinitrogen gas (N2) as a nitrogen source during bio-ethanol production are disclosed herein. Methods of bioethanol production using the chemically defined culture medium and culture conditions are also disclosed.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Paczesny, Sophie
Abstract
Disclosed are biomarker panels for evaluating subjects at risk of sinusoidal obstruction syndrome (SOS) early after hematopoietic stem cell transplantation (HSCT). In particular, the present disclosure relates to the use of one or more of ST2, ANG2, L-Ficolin, HA, and VCAM1 for prognosing, diagnosing, and/or treating SOS.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Chen, Peng-Sheng
Abstract
System and methods for monitoring and/or controlling nerve activity in a subject are provided. In one embodiment, a system includes electrodes configured to be placed proximate to a subject's skin, and a signal detector configured to detect electrical signals using the electrodes. The system also includes a signal processor configured to receive the electrical signals from the signal detector, and apply a filter to the received electrical signals to generate filtered signals, the filter configured to attenuate at least signals having frequencies corresponding to heart muscle activity during a heartbeat. The signal processor is also configured to identify a skin nerve activity using the filtered signals, estimate a sympathetic nerve activity using the identified skin nerve activity, and further to generate a report indicative of the estimated sympathetic nerve activity. In some aspects, the system further includes a signal generator to deliver the electrical stimulation to the subject's skin.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Chen, Peng-Sheng
Abstract
System and methods for monitoring and/or controlling nerve activity in a subject are provided. In one embodiment, a system includes electrodes configured to be placed proximate to a subject's skin, and a signal detector configured to detect electrical signals using the electrodes. The system also includes a signal processor configured to receive the electrical signals from the signal detector, and apply a filter to the received electrical signals to generate filtered signals, the filter configured to attenuate at least signals having frequencies corresponding to heart muscle activity during a heartbeat. The signal processor is also configured to identify a skin nerve activity using the filtered signals, estimate a sympathetic nerve activity using the identified skin nerve activity, and further to generate a report indicative of the estimated sympathetic nerve activity. In some aspects, the system further includes a signal generator to deliver the electrical stimulation to the subject's skin.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Tector, Joseph A.
Abstract
[0146] The application provides methods of improving a rejection related symptom, reducing premature separation and methods of producing a compound of interest with an altered epitope profile are provided. Knockout pigs with a disrupted gene or genes, and porcine organs, tissues, and cells therefrom are provided.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Chang, Ching-Pin
Abstract
Nucleic acids encoding modified myosin heavy-chain-associated RNA transcripts are provided. The modified myosin heavy-chain-associated RNA transcripts belongs to a cluster of long noncoding RNAs (lncRNA) and bind to chromatin remodeler Brg1 to inhibit Brg1's genomic targeting and gene regulation function. The modified myosin heavy-chain- associated RNA transcripts expressed in an individual inhibit Brg1's gene regulation function and protect the heart of the individual from myopathy and failure. One of the modified heavy- chain-associated RNAs is a 400 base pair fragment segmented from a natural 779 base pair sequence of Mhrt (Mhrt779) and has the same cardioprotective effects as the Mhrt779.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Tector Iii, A., Joseph
Abstract
The application provides methods of improving a rejection related symptom, reducing premature separation and methods of producing a compound of interest with an altered epitope profile are provided. Knockout pigs with a disrupted gene or genes, and porcine organs, tissues, and cells therefrom are provided.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Sardar, Rajesh
Korc, Murray
Joshi, Gayatri, K.
Abstract
Biosensors and methods for localized surface plasmon resonance biosensing are disclosed. The biosensor can include a substrate having a substrate surface to which a plurality of localized surface plasmon resonance (LSPR) antennae are affixed. The LSPR antennae can be affixed via an affixation surface of the LSPR antenna. The LSPR antennae can have a functional surface opposite the affixation surface. Each functional surface can be functionalized by a plurality of single-stranded DNA.
Indiana University Research & Technology Corp (USA)
Inventor
Mckinley, Todd O.
Steenburg, Scott D.
Abstract
Example embodiments are described that relate to the analysis of tissue damage in an injured patient. Example embodiments are methods and systems for collecting medical imaging data, identifying tissue damage in the medical imaging data, analyzing the tissue damage shown in the medical imaging data, and/or quantifying the tissue damage shown in the medical imaging data. The disclosed methods allow for determining a risk for multiple organ failure and systemic inflammation in a multiply injured patient.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
51.
Materials and methods to enhance hematopoietic stem cells engraftment procedures
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Chen, Peng-Sheng
Abstract
Systems and methods for controlling a ventricular rate during atrial fibrillation are provided. In some aspects, a method includes selecting a treatment protocol based on a determined condition of a subject, the treatment protocol comprising intermittent periods of electrical stimulation separated by periods of non-stimulation. The method also includes applying an electrical stimulation, according to the selected the treatment protocol, using an electrical source and at least one electrode positioned at locations associated with a vagal nerve of the subject to control a ventricular rate during atrial fibrillation.
Indiana University Research & Technology Corporation (USA)
Inventor
Gangaraju, Shekhar Raja
Abstract
Methods for the treatment and monitoring of diabetic retinopathy are provided. More specifically, the method for the treatment of diabetic retinopathy comprises administering to an individual suspected of having diabetic retinopathy a composition comprising an agent that inhibits the activity or expression of EMAPII or CXCR3. Methods for diagnosing and monitoring the progression of diabetic retinopathy in an individual, or monitoring the efficacy of a therapy for diabetic retinopathy are provided. More specifically, the method comprises determining the levels of EMAPII in a biological sample from an individual and comparing them to a control or reference sample, or a chronological sample from the individual.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07C 255/47 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Gutwein, Luke, G.
Sood, Rajiv
Tholpady, Sunil, S.
Abstract
A method and apparatus for extracting tissue samples are disclosed herein. An example apparatus disclosed herein includes a first sidewall and a second sidewall spaced apart from the first sidewall. The example apparatus also includes a track to receive a blade between the first sidewall and the second sidewall. The track is to guide the blade to penetrate skin of a patient to a predetermined depth of invasion.
Indiana University Research & Technology Corporation (USA)
Inventor
Izadian, Afshin
Bacallao, Robert L.
Abstract
A system, device and apparatus for measuring electrolytes, where an electrical charge is applied to a measurement portion to draw ions from a liquid to a gel-solution via at least one electric field. The gel-solution containing the extracted ions is excited with light of a predetermined wavelength from an emitter. A receiver detects the illumination of the ions as a result of the excited gel-solution, and a processor converts the detected intensities of the illumination to a biologically useful value representing ionic concentration.
Indiana University Research & Technology Corporation (USA)
Inventor
Lu, Hau
Zeng, Shelya
Zhang, Qi
Ye, Qizhuang
Ding, Derong
Abstract
+/+ cells. This INZ analog exhibited a much lower effect on p53-null H1299 cells and importantly no toxicity towards normal human p53-containing WI-38 cells. Those results also reveal key chemical features for INZ activity, and identify the newly synthesized INZ analog 37 as a better small molecule for further development of anti-cancer therapies.
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/538 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
58.
Methods of modulating thrombocytopenia and modified transgenic pigs
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Tector, Iii, Alfred Joseph
Burlak, Christopher
Abstract
The application provides methods of modulating platelet uptake by liver sinusoidal endothelial cells and of modulating thrombocytopenia. Transgenic pigs modified to bind fewer platelets are provided.
Indiana University Research & Technology Corporation (USA)
Inventor
Hashino, Eri
Oxford, Gerry
Koehler, Karl R.
Abstract
Disclosed herein are methods and compositions for generating cultures and isolated cell populations containing preplacodal ectoderms cells, otic placode cells, and inner ear sensory hair cells derived from pluripotent cells by modulating TGFβ, BMP, and FGF signaling pathways under defined culture conditions. Also described are methods for obtaining non-otic placodal tissues from pluripotent stem cells. Methods for identifying agents that induce or enhance differentiation and generation of hair cells are also disclosed. Methods for identifying cytoprotective agents for hair cells are also described.
Indiana University Research & Technology Corporation (USA)
Inventor
Xie, Jian
Wang, Meixian
Abstract
A carbon composite material, including a plurality of spaced graphene sheets, each respective sheet having opposed generally planar surfaces, and a plurality of functionalized carbonaceous particles. At least some functionalized carbonaceous particles are disposed between any two adjacent graphene sheets, and each respective at least some functionalized carbonaceous particle is attached to both respective any two adjacent graphene sheets. Each respective graphene sheet comprises at least one layer of graphene and at least portions of respective any two adjacent graphene sheets are oriented substantially parallel with one another.
H01M 4/583 - Carbonaceous material, e.g. graphite-intercalation compounds or CFx
B32B 5/16 - Layered products characterised by the non-homogeneity or physical structure of a layer characterised by features of a layer formed of particles, e.g. chips, chopped fibres, powder
B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
H01G 11/34 - Carbon-based characterised by carbonisation or activation of carbon
B05D 1/18 - Processes for applying liquids or other fluent materials performed by dipping
B32B 37/18 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by the properties of the layers with all layers existing as coherent layers before laminating involving the assembly of discrete sheets or panels only
B05D 3/10 - Pretreatment of surfaces to which liquids or other fluent materials are to be appliedAfter-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials by other chemical means
B01J 20/20 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising free carbonSolid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising carbon obtained by carbonising processes
B01D 53/02 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography
B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
B32B 9/00 - Layered products essentially comprising a particular substance not covered by groups
B32B 3/08 - Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shapeLayered products comprising a layer having particular features of form characterised by features of form at particular places, e.g. in edge regions characterised by added members at particular parts
B82Y 40/00 - Manufacture or treatment of nanostructures
C01B 3/00 - HydrogenGaseous mixtures containing hydrogenSeparation of hydrogen from mixtures containing itPurification of hydrogen
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Bacallao, Robert
Abstract
The invention provides a catheter and control box apparatus and related methods that are useful in delivering liquids, including liquids comprising nucleic acid molecules into cells. In particular, the invention provides a catheter that stabilizes fluid flow within a vein to deliver a volume, pressure charge of saline solution, exogenous compositions, and isolated vectors to kidney cells, using the renal vein as a guide and under hydrodynamic pressure. The catheter and control box apparatus and related methods described herein are useful to research, prognose, ameliorate symptoms of kidney injury, and treat kidney pathologies.
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Bacallao, Robert
Abstract
The invention provides a catheter and control box apparatus and related methods that are useful in delivering liquids, including liquids comprising nucleic acid molecules into cells. In particular, the invention provides a catheter that stabilizes fluid flow within a vein to deliver a volume, pressure charge of saline solution, exogenous compositions, and isolated vectors to kidney cells, using the renal vein as a guide and under hydrodynamic pressure. The catheter and control box apparatus and related methods described herein are useful to research, prognose, ameliorate symptoms of kidney injury, and treat kidney pathologies.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (USA)
Inventor
Zhang, Zhong-Yin
Kontaridis, Maria
Zeng, Li-Fan
Wang, Jianxun
Abstract
Methods are disclosed herein for administering a oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitor for treating autoimmune and/or glomerulonephritis-associated diseases, and in particular, Systemic Lupus Erythematosus (SLE).
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Blazer-Yost, Bonnie
Abstract
Compositions and methods are described herein for the treatment of cystic diseases using PPARγ modulators. In particular, compositions and methods are described herein for the treatment of cystic diseases using low doses of PPARγ modulators.
A61K 31/421 - 1,3-Oxazoles, e.g. pemoline, trimethadione
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/185 - AcidsAnhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
A61P 15/00 - Drugs for genital or sexual disordersContraceptives
65.
Methods for the diagnosis and treatment of neurological disorders
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Torres, Elizabeth B.
Jose-Valenzuela, Jorge
Abstract
The present invention provides objective methods of diagnosis and behavioral treatments of neurological disorders such as autism spectral disorders and Parkinson's disease.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/16 - Devices for psychotechnicsTesting reaction times
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
H04L 29/06 - Communication control; Communication processing characterised by a protocol
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
66.
COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (Republic of Korea)
Inventor
Corson, Timothy W.
Basavarajappa, Halesha D.
Seo, Seung-Yong
Lee, Bit
Fei, Xiang
Abstract
Synthetic cremastranone and cremastranone analogs are disclosed. Additionally, methods for synthesizing cremastranone and cremastranone analogs are disclosed. Methods of treating ocular neovascularization disorders and treating angiogenesis-mediated disease are also disclosed.
C07D 311/18 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
C07D 311/74 - Benzo [b] pyrans, hydrogenated in the carbocyclic ring
67.
COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (Republic of Korea)
Inventor
Corson, Timothy W.
Basavarajappa, Halesha D.
Seo, Seung-Yong
Lee, Bit
Fei, Xiang
Abstract
Synthetic cremastranone and cremastranone analogs are disclosed. Additionally, methods for synthesizing cremastranone and cremastranone analogs are disclosed. Methods of treating ocular neovascularization disorders and treating angiogenesis-mediated disease are also disclosed.
C07D 311/18 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
C07D 311/74 - Benzo [b] pyrans, hydrogenated in the carbocyclic ring
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
68.
HYDROXYINDOLE CARBOXYLIC ACID BASED INHIBITORS FOR ONCOGENIC SRC HOMOLOGY-2 DOMAIN CONTAINING PROTEIN TYROSINE PHOSPHATASE-2 (SHP2)
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Zhang, Zhong-Yin
Zeng, Li-Fan
Abstract
Inhibitors of protein tyrosine phosphatases are disclosed. The inhibitors include hydroxyindole carboxylic acids having a linker and an amine scaffold that are potent inhibitors of Src homology 2-domain containing protein tyrosine phosphatase-2.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Zhang, Zhong-Yin
Zeng, Li-Fan
Abstract
Inhibitors of protein tyrosine phosphatases are disclosed. The inhibitors include hydroxyindole carboxylic acids having a linker and an amine scaffold that are potent inhibitors of Src homology 2-domain containing protein tyrosine phosphatase-2.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Du, Hong
Yan, Cong
Abstract
The present invention provides diagnostics for identifying and distinguishing various types of lung cancers using serum and/or bronchioalveolar lavage fluid. Signatures of secretory proteins are used to identify and distinguish lung cancers. The biomarker signatures may also be used to separate lung cancers from other inflammatory diseases, monitor progression, or assess treatment efficacy.
Indiana University Research & Technology Corporation (USA)
Inventor
Akingba, A. George
Fischer, Jr., Frank J.
Abstract
A guide catheter assembly includes an outer sheath and an inner catheter disposed, at least partially, within the outer sheath. A tether tethers the inner catheter to the outer sheath. The guide catheter assembly has a first configuration where the tether is untensioned and distal ends of the outer sheath and inner catheter are pointing in a first direction. In a second configuration of the guide catheter assembly, the tether is tensioned, the distal end of the outer sheath is pointing in the first direction, the distal end of the inner catheter is pointing in a second direction that is different from the first direction, and the tether is oriented at an angle different from both the first direction and the second direction.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
A61M 25/01 - Introducing, guiding, advancing, emplacing or holding catheters
Indiana University Research & Technology Corporation (USA)
Inventor
Huq, Ragibul
Anwar, Sohel
Abstract
Methods and apparatus for detecting the filtering state of a filter, such as a particulate filter. Some embodiments include one or more capacitive sensors that provide a signal corresponding to the filtered state of the filter with a change in measured capacitance. A novel ECT based sensing technique for soot load estimation in a diesel particulate filter is presented. The sensing technology is based on principle that deposited soot thickness inside DPF causes a variation in the dielectric constant which has a direct impact on the capacitance of ECT system and its output voltage. The sensor can be built into the DPF outer shell as indicated in the design. The simulation results demonstrate that there is a direct relationship between the amount of soot load in the DPF and the output voltage of the ECT system which can be used to estimate the soot load.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Gangaraju, Rajashekhar
Abstract
Methods for the treatment and monitoring of diabetic retinopathy are provided. More specifically, the method for the treatment of diabetic retinopathy comprises administering to an individual suspected of having diabetic retinopathy a composition comprising an agent that inhibits the activity or expression of EMAPII or CXCR3. Methods for diagnosing and monitoring the progression of diabetic retinopathy in an individual, or monitoring the efficacy of a therapy for diabetic retinopathy are provided. More specifically, the method comprises determining the levels of EMAPII in a biological sample from an individual and comparing them to a control or reference sample, or a chronological sample from the individual.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Chen, Peng-Sheng
Lin, Shien-Fong
Abstract
A system and method for monitoring nerve activity in a subject. The system includes a plurality of electrodes placed in proximity to skin of the subject, an amplifier electrically connected to the electrodes and configured to generate a plurality of amplified signals corresponding to electrical signals received from the subject through the electrodes, and a signal processor. The signal processor applies a high-pass filter to the amplified signals to generate filtered signals from the amplified signals, identifies autonomic nerve activity in the plurality of filtered signals; and generates an output signal corresponding to the filtered signals. The high-pass filter attenuates a plurality of the amplified signals having frequencies that correspond to heart muscle activity during a heartbeat.
Indiana University Research & Technology Corporation (USA)
Inventor
Whittam, Benjamin
Abstract
A system and method is provided for the deployment of a ureter between a kidney and a bladder. A stent includes a flexible internal drainage portion, a retention portion, and an external drainage portion. The external drainage portion includes a sharpened tip configured to be passed from through a renal pelvis and out the side of a patient's body from inside the ureter. The stent is arranged to be removable by pulling the external drainage portion and thereby removing the stent out the side of the body.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
A61M 27/00 - Drainage appliances for wounds, or the like
76.
DOUBLE KNOCKOUT (GT/CMAH-KO) PIGS, ORGANS AND TISSUES
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Tector, A., Joseph
Abstract
The invention provides double knockout transgenic pigs (GT/CMAH-KO pigs) lacking expression of any functional aGAL and CMAH. Double knockout GT/CMAH-KO transgenic organs, tissues and cells are also provided. Methods of making and using the GT/CMAH-KO pigs and tissue are also provided.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Zhang, Zhong-Yin
Zhang, Sheng
Abstract
Novel protein tyrosine phosphatase (PTP) inhibitor compounds synthesized from phosphonodifluoromethyl phenylalanine (F2Pmp) are provided. Use of these compounds for inhibiting a PTP enzyme (such as PTP-MEG2), as well as treating a disease, disorder, or condition associated with inappropriate activity of a PTP (such as type 2 diabetes), is also provided.
C07C 237/20 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Johnson, Raymond, M.
Abstract
Two patients diagnosed with KLS were treated. One patient had severe KLS that progressed to the equivalent of pediatric Kawasaki Disease Shock Syndrome (KDSS). The second patient had a typical KLS presentation and clinical course. Cytokines and chemokines provide inflammatory signatures in the serum that reflect the polarity of the immune response and the affected cell types. Multiplex ELISA technology was used to define the cytokine milieu in the serum of the two adult HIV patients with KLS during the acute and convalescent phases. Those sera were compared with sera from asymptomatic HIV subjects and a normal serum control. Those comparisons suggest that HIV KLS is a dysfunctional Th2 response to an unknown inciting agent in the vascular wall, and that a multiplex ELISA or similar technology based a limited combination of KLS/KD pathogenesis-related cytokines (IL-6, IL-13, sTNFRII) and endothelial/smooth muscle chemokines (CCL1, CCL2, CxCL11) may provide an objective tool for diagnosing KLS and Kawasaki Disease. Because KD and HIV KLS are the only known "Th2" vasculitidies that spare the lungs (unique clinical presentation) and include plasma cell infiltration of the vascular wall as a prominent histopathologic feature (unique pathophysiology), a diagnostic test based on combinations of the above analytes will be highly specific and therefore clinically useful.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Innes, Roger
Kim, Sang Hee
Qi, Dong
Abstract
Compositions, systems and methods are provided for conferring disease resistance to plant pathogens that use proteases to target plant substrate proteins inside plant cells. Briefly, the compositions, systems and methods are based upon plant substrate proteins that are targeted by pathogen-specific proteases and that activate nucleotide binding site-leucine rich repeat (NB-LRR) disease resistance proteins when cleaved by the protease. These substrate proteins are modified such that the endogenous protease recognition sequence is replaced by a protease recognition sequence specific to a different pathogen protease (i.e., a heterologous protease recognition sequence). The modified plant substrate protein therefore can be used in connection with its corresponding NB-LRR protein to activate resistance in response to cleavage by the heterologous pathogen-specific protease. When activated by the plant pathogen-specific protease, the pair initiates host defense responses thereto, including programmed cell death.
Indiana University Research & Technology Corporation (USA)
Inventor
Wang, Xiaofeng
Tang, Haixu
Chen, Yangyi
Peng, Bo
Abstract
System and methods are provided for performing privacy-preserving, high-performance, and scalable DNA read mapping on hybrid clouds including a public cloud and a private cloud. The systems and methods offer strong privacy protection and have the capacity to process millions of reads and allocate most of the workload to the public cloud at a small overall cost. The systems and methods perform seeding on the public cloud using keyed hash values of individual sequencing reads' seeds and then extend matched seeds on the private cloud. The systems and methods are designed to move the workload of read mapping from the extension stage to the seeding stage, thereby ensuring that the dominant portion of the overhead is shouldered by the public cloud.
H04L 29/06 - Communication control; Communication processing characterised by a protocol
G06F 19/22 - for sequence comparison involving nucleotides or amino acids, e.g. homology search, motif or Single-Nucleotide Polymorphism [SNP] discovery or sequence alignment
G06F 19/28 - for programming tools or database systems, e.g. ontologies, heterogeneous data integration, data warehousing or computing architectures
H04L 9/06 - Arrangements for secret or secure communicationsNetwork security protocols the encryption apparatus using shift registers or memories for blockwise coding, e.g. D.E.S. systems
H04L 9/32 - Arrangements for secret or secure communicationsNetwork security protocols including means for verifying the identity or authority of a user of the system
81.
COMPOUNDS FOR TREATMENT OF SPINAL MUSCULAR ATROPHY
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (USA)
THE UNIVERSITY OF MASSACHUSETTS (USA)
Inventor
Androphy, Elliot J.
Cherry, Jonathon J.
Cuny, Gregory D.
Glicksman, Marcie A.
Abstract
Disclosed herein are compositions and methods for treatment of spinal muscular atrophy (SMA). In certain embodiments, compounds are provided that increase full-length survival of motor neuron (SMN) protein production by an SMN2 gene.
C07D 261/06 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORP. (USA)
Inventor
Ortoleva, Peter J.
Abstract
Systems and methods for computer-aided vaccine design may comprise performing one or more molecular dynamics simulations of a protein assembly having at least one epitope, determining a fluctuation measurement for the at least one epitope using the one or more molecular dynamics simulations, and predicting the immunogenicity of the protein assembly in response to the fluctuation measurement are disclosed.
G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
G16B 15/00 - ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Hashino, Eri
Oxford, Gerry
Koehler, Karl, R.
Abstract
Disclosed herein are methods and compositions for generating cultures and isolated cell populations containing preplacodal ectoderms cells, otic placode cells, and inner ear sensory hair cells derived from pluripotent cells by modulating TGFβ, BMP, and FGF signaling pathways under defined culture conditions. Also described are methods for obtaining non-otic placodal tissues from pluripotent stem cells. Methods for identifying agents that induce or enhance differentiation and generation of hair cells are also disclosed. Methods for identifying cytoprotective agents for hair cells are also described.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Chen, Jie
Xia, Zeyang
Abstract
A handheld orthodontic tool includes a housing, electric motor, and a probe configured to engage a tooth. An operator applies manual pressure to the tooth with the probe, and the electric motor activates to vibrate the tooth through the probe. The orthodontic tool enables accelerating individual tooth or a group of teeth during orthodontic treatment to reach differential tooth movement speed, which will shorten the treatment time and reduce side effects including root resorption and anchorage loss.
A61C 7/00 - Orthodontics, i.e. obtaining or maintaining the desired position of teeth, e.g. by straightening, evening, regulating, separating, or by correcting malocclusions
A61C 7/10 - Devices having means to apply outwardly directed force, e.g. expanders
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Campbell, Joseph
Brown, Wayman
Bang, Kyung-Hoon
Bonte, Rory
Finnell, John
Aldawsari, Mohammed
Abstract
An identifier for a conduit includes a substrate having a pair of apertures. The substrate further contains a frangible portion encompassing one of the apertures and having a shape that corresponds to an opening left in the substrate after removal of the frangible portion. The identifier enables the shape of the frangible portion to be correlated with the shape of the opening left in the substrate after the frangible portion is separated from the substrate.
H02G 1/08 - Methods or apparatus specially adapted for installing, maintaining, repairing, or dismantling electric cables or lines for laying cables, e.g. laying apparatus on vehicle through tubing or conduit, e.g. rod or draw wire for pushing or pulling
86.
A BIOMARKER FOR DETERMINING MITOCHONDRIAL DAMAGE IN FRIEDREICH'S ATAXIA
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Payne, Ronald Mark
Wagner, Gregory R.
Babbey, Clifford M.
Pride, P. Melanie
Abstract
Compositions and methods for screening for a disease or a disorder associated with a deficiency in frataxin in a subject using biomarkers for diseases or disorders associated with a deficiency in frataxin are disclosed. The compositions and methods include determining the acetylation status of mitochondrial proteins. Also disclosed are methods of detecting progression of a disease or a disorder associated with a deficiency in frataxin in a subject and methods of monitoring effectiveness of a therapy for diseases or disorders associated with a deficiency in frataxin.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Thibos, Larry N.
Abstract
One exemplary embodiment is a method for determining an ophthalmic prescription. An examination room is lighted to simulate daytime viewing and a conventional eye chart is used as a visual stimulus. A first corrective spherical lens power is determined by varying spherical lens power and identifying when perceived vision is best. The examination room is kept dark to simulate nighttime viewing conditions. The visual stimulus utilized is a white point source on a dark background, or a self illuminated symbol on a dark background. A second corrective spherical lens powered is determined by varying spherical lens power and identifying when perceived vision is best. An ophthalmic prescription such as one or more lenses, one or more surgical corrections or a combinations thereof is provided including a first corrective component including the first preferred spherical lens power, and a second corrective component including the second preferred spherical lens power.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Karmazyn, Boaz
Liang, Yun
Abstract
A CT scanner and method of operating the CT scanner enables customized automated selection of tube current and peak tube voltage for a CT scan. The CT scanner receives data, each datum of which corresponds to a reference image quality (noise level at a certain tube voltage) for patient water equivalent diameter (WED) body size. The CT scanner then stores the noise level and patient WED, and a processor in the CT scanner generates a curve corresponding to acceptable noise levels as a function of water equivalent diameter. The CT scanner stores the curve in a memory associated with the scanner and the CT scanner is subsequently operated with reference to the curve stored in the memory. The tube voltage that can generate the reference CT scan quality (signal-tonoise ratio) with the lowest radiation dose to the patient is selected.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Tector, Alfred, Joseph Iii
Paris, Leela, L.
Abstract
Compositions are provided that include transgenic, non-human mammals, as well as organs, tissue and cells derived therefrom that express at least one heterologous immune- inhibitory molecule such as signal-regulatory protein alpha. Methods of using such transgenic, non-human mammals, organs, tissue and cells derived therefrom are provided for modulating the complications, issues and risks associated with xenotransplantation.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Payne, R. Mark
Babbey, Clifford M.
Martin, Kyle B.
Beard, Samuel M.
Abstract
The present disclosure relates generally to fusion proteins including gigaxonin coupled to a cell penetrant peptide. These fusion proteins can be used to treat GAN in a subject in need thereof. Administration of the fusion proteins allows for control of at least one of Galectin-1 (GAL-1) levels and phosphorylated vimentin protein levels, thereby mediating aggregation of vimentin and the formation of vimentin-free zones in cells.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 25/00 - Drugs for disorders of the nervous system
91.
Rho kinase inhibitors for treatment of mastocytosis and acute myeloid leukemia
Indiana University Research & Technology Corporation (USA)
Inventor
Kapur, Reuben
Abstract
The disclosure is directed to methods of treating hematologic malignancies. More particularly, the disclosure is directed to methods of treating hematologic malignancies using Rho kinase (ROCK) inhibitors and myosin light chain-specific inhibitory RNA molecules. The disclosure is further directed to methods of identifying drug candidates for inhibiting ROCK in hematologic malignancies.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Goodpaster, John
Abstract
A biodegradation suppression system may include an anti-microbial agent, wherein the anti-microbial agent is effective to suppress biodegradation of ignitable liquid residues within a forensic sample. The biodegradation suppression system for use with a forensic sample may also include a solution including triclosan, wherein the solution suppresses biodegradation of ignitable liquid residues within a forensic sample for a period of time. The biodegradation suppression system for use with a forensic sample may also include a solution including triclosan, wherein the solution suppresses biodegradation of gasoline, wherein the solution is effective to allow for identification of at least one component of gasoline within the forensic sample.
A01N 25/02 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
A01N 59/08 - Alkali metal chloridesAlkaline earth metal chlorides
A01N 29/08 - Halogen directly attached to a polycyclic ring system
93.
MATERIALS AND METHODS FOR IDENTIFYING PATIENTS SUSCEPTIBLE TO DEVELOPING TAXANE INDUCED NEUROPTHY
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Radovich, Milan
Schneider, Bryan, P.
Abstract
A randomized phase III study with a planned accmal (n=4950); GWAS performed ors 2204 patients to compare genotypes with efficacy and toxicities. The phenotype for this study is time to first grade 2-4 neuropathy. GVVAS is conducted using the Xnfmium HumanOmnil platform from Illumma which assessed 1.2 million SNPs per patient. Comparisons are made using Cox regression analysis with correction for multiple comparisons (Bonferroni) and established clinical trial co-variates (race, age, tumor size, LN status). Toxicity data indicates that 576 patients experienced grade 2-4 neuropathy and 1633 did not. Clinical predictors for neuropathy include age (12.9% increase with each decade; p=0.004) and African American race (HR=2.1; p=4.5 x 10-11). Six SNPs with MAF>5% demonstrate associations with neuropathy (ρ<5χ 10-7). These SNPs reside in two genes: RWDD3 and TECTA. A missense SNP in RWDD3 demonstrates % neuropathy at 15 months follow-up: 27% for homozygous wild-type, 40% for heterozygotes, and 60% for homozygous variant (allele dose-effect: HR=1.5; p=8.5 χ 10-8). Multiple other SNPs with MAF<5% were also associated with neuropathy (p<5x 10-7).
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Akingba, A. George
Chen, Peng-Sheng
Mahmood, Aamer
Abstract
An electrode for monitoring nerve activity has been developed. The electrode includes an array of electrically conductive projections extending from a surface of an electrical contact that enable the electrical contact to be connected directly to the nerve.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Chen, Peng-Sheng
Lin, Shien-Fong
Chen, Lan, S.
Abstract
A method of nerve stimulation produces therapeutic effects in an organ not directly innervated by the electrically stimulated nerve. The method includes identifying an electrical stimulation reaction threshold of at least one organ directly innervated by a parasympathetic nerve of a subject, identifying a reaction threshold of at least one tissue that is not directly innervated by the parasympathetic nerve of the subject after the parasympathetic nerve is electrically stimulated, and electrically stimulating the parasympathetic nerve with an electrical stimulation signal that is below the identified reaction threshold for the at least one directly innervated organ, but above a reaction threshold for the at least one tissue or organ that is not directly innervated by the parasympathetic nerve of the subject.
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Agarwal, Mangilal
Varahramyan, Khodadad
Shrestha, Sudhir
Abstract
A solar cell. The solar cell includes a substrate, a first layer comprising a first copper-based material deposited upon the substrate, the first copper-based material electrically attracted to the substrate or to a first optional deposit layer deposited between the substrate and the first layer, and a second layer comprising a second copper-based material deposited upon the first layer or an second optional deposit layer deposited between the first layer and the second layer, the second copper-based material electrically attracted to the first layer or to the second optional deposit layer, wherein the first copper-based material and the second copper-based material are selected from the group consisting of copper indium gallium (di)selenide (CIGS), copper indium selenium (CIS), and cadmium sulfate (CdS).
Indiana University Research & Technology Corporation (USA)
Inventor
Erickson, Craig A.
Abstract
The present invention is directed to a method of treating a subject with autism spectrum disorder by administering an acetylaminopropane sulfonate. The acetylaminopropane sulfonate may have the following formula
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
A61K 31/00 - Medicinal preparations containing organic active ingredients
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Chen, Peng-Sheng
Lin, Shien-Fong
Abstract
A method has been developed that detects cardiac arrhythmia from intrinsic cardiac nerve signals obtained from a heart in a patient. The method includes sampling intrinsic cardiac nerve activity at a high sample rate, filtering the sampled signal with a high pass filter, comparing the filtered signal to a predetermined threshold, and initiating a therapeutic action in response to the filtered signal exceeding the predetermined threshold. The intrinsic cardiac nerve activity may be received through an electrode implanted on the heart or from an electrode inserted into the venous structure of the heart.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
A61B 5/04 - Measuring bioelectric signals of the body or parts thereof
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
Izadian, Afshin
Abstract
A wind power conversion apparatus for efficiently generating electric power is disclosed. The apparatus includes at least one blade, the at least one blade being configured to rotate when exposed to wind, a fluid pump mechanically coupled to the at least one blade and configured to pressurize fluid from a low pressure fluid to a high pressure fluid, a fluid motor fluidly coupled to the fluid pump and configured to rotate an output shaft in response to the high pressure fluid and thereby providing the low pressure fluid, and an electric generator mechanically coupled to the fluid motor and configured to generate electric power in response to the rotation of the output shaft of the fluid motor.